Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats

Hypertension Research

Volumn 36, Issue 4, 2013, Pages 342-348

  Takai, Shinji ^a   Jin, Denan ^a   Aritomi, Shizuka ^b   Niinuma, Kazumi ^b   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b AJINOMOTO CO INC   (Japan)

Author keywords

angiotensin II receptor blocker; calcium channel blocker; NADPH oxidase; oxidative stress; vascular function

Indexed keywords

4 HYDROXYNONENAL; AMLODIPINE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; CILNIDIPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; RENIN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; HYPERTENSION; MALE; NONHUMAN; RAT;

ALDEHYDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; CAROTID ARTERIES; CYSTEINE PROTEINASE INHIBITORS; DIHYDROPYRIDINES; HEART; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NADH, NADPH OXIDOREDUCTASES; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REAL-TIME POLYMERASE CHAIN REACTION; TETRAZOLES; VALINE; VASCULAR DISEASES;

EID: 84877132476     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.187     Document Type: Article

References (37)

1. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
2. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/-NAD(P)H oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
3. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
4. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, Horiuchi M. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens 2009; 22: 145-150.
5. Takai S, Jin D, Shimosato T, Sakonjo H, Miyazaki M. Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. Hypertens Res 2011; 34: 245-252.
6. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
7. Fujisawa T, Ikegami H, Noso S, Hiromine Y, Kawabata Y, Nishino M, Asano K, Ogihara T. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy. J Diabetes Complications 2007; 21: 252-257.
8. Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetatesalt hypertensive rats. Hypertens Res 2011; 34: 521-529.
9. Honda M, Hayashi K, Matsuda H, Kubota E, Tokuyama H, Okubo K, Takamatsu I, Ozawa Y, Saruta T. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens 2001; 19: 2031-2037.
10. Takai S, Jin D, Sakonjo H, Miyazaki M. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. Hypertens Res 2010; 33: 953-959.
11. Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ, Tsien RW. Dominant role of N-type Ca2+ channels in evoked release of noradrenaline from sympathetic neurons. Science 1988; 239: 57-61.
12. Morimoto S, Yano Y, Maki K, Iwasaka T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens 2007; 25: 2178-2183.
13. Takai S, Jin D, Ikeda H, Sakonjo H, Miyazaki M. Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens Res 2009; 32: 853-860.
14. Takai S, Jin D, Miyazaki M. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor g. J Pharmacol Sci 2011; 116: 309-315.
15. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, Sueta D, Koibuchi N, Yamamoto E, Ogawa H, Kim-Mitsuyama S. Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats. J Pharmacol Exp Ther 2011; 339: 358-866.
16. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999; 33: 1353-1358.
17. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002; 20: 281-286.
18. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593-600.
19. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-413.
20. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers 4th Q, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
21. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002; 40: 755-762.
22. Hishikawa K, Takase O, Idei M, Fujita T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76: 230-231.
23. Lee YJ, Park KH, Park HH, Kim YJ, Lee KY, Kim SH, Koh SH. Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway. J Neurochem 2009; 111: 90-100.
24. Macarthur H, Westfall TC, Wilken GH. Oxidative stress attenuates NO-induced modulation of sympathetic neurotransmission in the mesenteric arterial bed of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2008; 294: H183-H189.
25. Miyagawa K, Ohashi M, Yamashita S, Kojima M, Sato K, Ueda R, Dohi Y. Increased oxidative stress impairs endothelial modulation of contractions in arteries from spontaneously hypertensive rats. J Hypertens 2007; 25: 415-421.
26. Brosnihihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27: 523-528.
27. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensinconverting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: e1-e9.
28. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA. Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice. Hypertension 2008; 51: 574-580.
29. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 2011; 34: 154-160.
30. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-976.
31. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289: H1013-H1019.
32. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, Nitta K. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensinaldosterone system in SHR/Izm. Am J Nephrol 2009; 30: 155-161.
33. Aritomi S, Niinuma K, Ogawa T, Konda T, Nitta K. Effects of an N-type calcium antagonist on angiotensin II-renin feedback. Am J Nephrol 2011; 33: 168-175.
34. Tom B, de Vries R, Saxena PR, Danser AH. Bradykinin potentiation by angiotensin-(1- 7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 2001; 38: 95-99.
35. Fan L, Yang Q, Xiao XQ, Grove KL, Huang Y, Chen ZW, Furnary A, He GW. Dual actions of cilnidipine in human internal thoracic artery: inhibition of calcium channels and enhancement of endothelial nitric oxide synthase. J Thorac Cardiovasc 2011; 141: 1063-1069.
36. Sharma A, Trane A, Yu C, Jasmin JF, Bernatchez P. Amlodipine increases endothelial nitric oxide release by modulating binding of native eNOS protein complex to caveolin- 1. Eur J Pharmacol 2011; 659: 206-212.
37. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609-614.